Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie

Trial Profile

Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azelnidipine (Primary) ; Trichlormethiazide (Primary) ; Amlodipine; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms RANDAM
  • Most Recent Events

    • 04 Oct 2012 Primary endpoint 'Urinary-albumin:creatinine-ratio' has been met.
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 06 Apr 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top